Synovial fluid and plasma concentrations of tedizolid in patients with osteoarthritis infected with Staphylococcus aureus effectively determined with fluorescence detection.

IF 1.2 Q4 PHARMACOLOGY & PHARMACY

Journal of Pharmaceutical Health Care and Sciences Pub Date : 2023-10-10 DOI:10.1186/s40780-023-00303-z

Daisuke Negishi, Okimichi Mitsumatsu, Hiromi Mitsumatsu, Miaki Makiguchi, Makiko Shimizu, Hiroshi Yamazaki

{"title":"Synovial fluid and plasma concentrations of tedizolid in patients with osteoarthritis infected with Staphylococcus aureus effectively determined with fluorescence detection.","authors":"Daisuke Negishi, Okimichi Mitsumatsu, Hiromi Mitsumatsu, Miaki Makiguchi, Makiko Shimizu, Hiroshi Yamazaki","doi":"10.1186/s40780-023-00303-z","DOIUrl":null,"url":null,"abstract":"Background: Tedizolid is a new oxazolidinone antibiotic with high potency for the treatment of infections caused by methicillin-resistant Staphylococcus aureus and other species.Case presentation: Two patients with osteoarthritis (women aged 79 and 73 years, cases 1 and 2, respectively) infected with S. aureus were successfully treated with tedizolid after administration of 200 mg once daily via intravenous infusion. The synovial fluid and plasma concentrations of tedizolid during surgery in case 1 at day 7 were 2.1 and 1.6 µg/mL, respectively, yielding a ratio of synovial fluid/plasma of 130%. Those in case 2 at day 2 were 2.9 and 3.3 µg/mL, respectively, corresponding to a ratio of synovial fluid/plasma of 88%.Conclusions: These results imply very similar concentrations of tedizolid in the synovial fluid and plasma of osteoarthritis patients with acute S. aureus infection.","PeriodicalId":16730,"journal":{"name":"Journal of Pharmaceutical Health Care and Sciences","volume":"9 1","pages":"33"},"PeriodicalIF":1.2000,"publicationDate":"2023-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563349/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Health Care and Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s40780-023-00303-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tedizolid is a new oxazolidinone antibiotic with high potency for the treatment of infections caused by methicillin-resistant Staphylococcus aureus and other species.

Case presentation: Two patients with osteoarthritis (women aged 79 and 73 years, cases 1 and 2, respectively) infected with S. aureus were successfully treated with tedizolid after administration of 200 mg once daily via intravenous infusion. The synovial fluid and plasma concentrations of tedizolid during surgery in case 1 at day 7 were 2.1 and 1.6 µg/mL, respectively, yielding a ratio of synovial fluid/plasma of 130%. Those in case 2 at day 2 were 2.9 and 3.3 µg/mL, respectively, corresponding to a ratio of synovial fluid/plasma of 88%.

Conclusions: These results imply very similar concentrations of tedizolid in the synovial fluid and plasma of osteoarthritis patients with acute S. aureus infection.

Abstract Image

查看原文本刊更多论文

荧光检测法有效测定了感染金黄色葡萄球菌的骨关节炎患者滑液和血浆中替地固体的浓度。

背景：特地固体是一种新型恶唑烷酮类抗生素，对耐甲氧西林金黄色葡萄球菌等引起的感染具有较高的治疗效力。病例介绍：两名感染金黄色葡萄球菌的骨关节炎患者（分别为79岁和73岁的女性，病例1和2）在静脉滴注200mg每日一次后，成功地用替地唑治疗。病例1在第7天手术期间的滑液和血浆浓度分别为2.1和1.6µg/mL，滑液/血浆的比例为130%。病例2在第2天的浓度分别为2.9和3.3µg/mL，相当于滑液/血浆的比例为88%。结论：这些结果表明，患有急性金黄色葡萄球菌感染的骨关节炎患者滑液和血浆中的替地固体浓度非常相似。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊